Literature DB >> 2435003

Ribavirin antagonizes the effect of azidothymidine on HIV replication.

M W Vogt, K L Hartshorn, P A Furman, T C Chou, J A Fyfe, L A Coleman, C Crumpacker, R T Schooley, M S Hirsch.   

Abstract

Azidothymidine and ribavirin both inhibit replication of human immunodeficiency virus in vitro and show promise of clinical utility in patients infected with this virus. In this study, the possible interactions of these drugs were examined in vitro, and a reproducible antagonism between azidothymidine and ribavirin was found to occur under a variety of experimental conditions. The mechanism responsible for this antagonism appeared to be inhibition of azidothymidine phosphorylation by ribavirin. Because similar effects may occur in vivo, clinical trials of these two drugs in combination must be performed only under carefully controlled conditions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2435003     DOI: 10.1126/science.2435003

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  64 in total

Review 1.  Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infections.

Authors:  K E Nelson; D L Thomas
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 2.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

4.  Evaluation of the antiviral effect of new compounds by using cellular cultures.

Authors:  F Dianzani; G Antonelli
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

Review 5.  Problems in pharmacokinetic investigations in patients with HIV infection.

Authors:  J D Unadkat; J M Agosti
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of zidovudine. An overview of current data.

Authors:  J M Collins; J D Unadkat
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

7.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 8.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.

Authors:  H Ma; S Le Pogam; S Fletcher; F Hinojosa-Kirschenbaum; H Javanbakht; J-M Yan; W-R Jiang; N Inocencio; K Klumpp; I Nájera
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 10.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.